Information Provided By: 
Fly News Breaks for February 16, 2018
AVXS, BIIB
Feb 16, 2018 | 07:57 EDT
As reported earlier, Argus analyst David Toung downgraded Biogen (BIIB) to Hold from Buy due to increased competition for the company's multiple sclerosis drugs, anticipating related sales to slow from Q4 when results were boosted by "one-time factors". The analyst also points to delays in the clinical trials of aducanumab as well as competition for its gene therapy Spinraza product from Avexis (AVXS) next year.
News For BIIB;AVXS From the Last 2 Days
